1. Number of patients undergoing conservative treatment during the month |
1.00 |
2. Hemoglobin value of patients under conservative treatment |
1.00 |
3. Phosphorus value of a patient under conservative treatment |
1.00 |
4. Patients under conservative treatment referred for dialysis and with matured AVF |
0.89 |
5. Patients under conservative treatment who abandoned treatment |
0.89 |
6. Hospitalization of patients under conservative treatment due to clinical complications |
1.00 |
7. Monthly number of patients on peritoneal dialysis |
0.89 |
8. Tenckhoff catheter implantation |
0.89 |
9. Changing the peritoneal dialysis catheter extension |
0.89 |
10. Infection of tenckhoff catheter (signs/symptoms) |
0.89 |
|
10.1. Infection of tenckhoff catheter (access removed) |
0.89 |
|
10.2. Infection of tenckhoff catheter (laboratory tests collected) |
0.89 |
|
10.3. Infection of tenckhoff catheter (used antibiotic) |
0.89 |
|
10.4. Infection of tenckhoff catheter (result of peritoneal fluid culture/swab) |
0.89 |
11. Peritonitis in patients with APD and CAPD |
0.89 |
12. Hospitalization of patients on peritoneal dialysis due to clinical complications |
0.89 |
13. Hemoglobin value in patients on peritoneal dialysis |
0.89 |
14. Value of albumin in patients on peritoneal dialysis |
0.89 |
15. Phosphorus value in patients on peritoneal dialysis |
0.89 |
16. PTH value of patients on peritoneal dialysis |
0.89 |
17. Death in patients on peritoneal dialysis |
0.89 |
18. Patients eligible for transplant and older than 6 months on peritoneal dialysis, enrolled in the CNPDO |
0.89 |
19. Number of patients with chronic kidney disease on dialysis |
1.00 |
20. Number of patients with acute kidney disease on dialysis |
1.00 |
21.Short-term central venous catheter implantation (local) |
1.00 |
|
21.1. Short-term central venous catheter implantation (reason) |
1.00 |
|
21.2. Short-term central venous catheter implantation (withdrawal date) |
1.00 |
|
21.3. Short-term central venous catheter implantation (length of use) |
0.89 |
22. Long-term central venous catheter implantation (site, reason, date of withdrawal, length of use) |
1.00 |
|
22.1. Long-term central venous catheter implantation (reason) |
1.00 |
|
22.2. Long-term central venous catheter implantation (withdrawal date) |
0.89 |
|
22.3. Long-term central venous catheter implantation (length of use) |
0.89 |
23. Preparation of AVF (site: brachy basic; brachiocephalic; femoral; radiocephalic; ulnar-basilic;). Manufacture of polytetrafluoroethylene (PTFE) prosthesis. |
0.89 |
24. Short-term catheter infection/double lumen-CDL catheter (signs/symptoms) |
1.00 |
|
24.1. Short-term central venous catheter infection/double lumen-CDL catheter (access removed) |
1.00 |
|
24.2. Short-term central venous catheter infection/double lumen-CDL catheter (laboratory tests taken) |
1.00 |
|
24.3. Short-term central venous catheter infection/double lumen-CDL catheter (antibiotic used) |
1.00 |
|
24.4. Short-term central venous catheter infection/double lumen-CDL catheter (duration of antibiotic use) |
1.00 |
|
24.5. Short-term central venous catheter infection/double lumen-CDL catheter (culture result/swab) |
1.00 |
25. Long-term central venous catheter infection/Permicath® (signs/symptoms) |
1.00 |
|
25.1. Long-term central venous catheter infection/Permicath® (access removed) |
1.00 |
|
25.2. Long-term central venous catheter infection/Permicath® (laboratory tests taken) |
1.00 |
|
25.3. Long-term central venous catheter infection/Permicath® (antibiotic used) |
1.00 |
|
25.4. Long-term central venous catheter infection/Permicath® (length of antibiotic use) |
1.00 |
|
25.5. Long-term central venous catheter/Permicath® infection (culture result/swab) |
1.00 |
26. AVF infection and prosthesis (signs/symptoms, laboratory tests taken, antibiotic used, culture result/swab) |
0.89 |
|
26.1. AVF infection and prosthesis (laboratory tests taken) |
0.89 |
|
26.2. AVF infection and prosthesis (used antibiotic) |
0.89 |
|
26.3. AVF infection and prosthesis (result of culture/swab) |
0.89 |
27. AVF thrombosis |
0.89 |
28. PTFE prosthetic thrombosis |
0.89 |
29.Loss of AVF |
1.00 |
30. Other types of infection during the period (urinary tract infection) |
1.00 |
|
30.1. Other types of infection during the period (intestinal infection or abdominal focus) |
0.89 |
|
30.2. Other types of infection during the period (surgical site) |
0.89 |
|
30.3. Other types of infection during the period (skin infection: parasitic infestation or infectious cellulitis) |
0.89 |
|
30.4. Other types of infection during the period (respiratory infection/pneumonia) |
0.89 |
31. Number of dialysis patients using a short-term central venous catheter on the last day of dialysis of the month |
1.00 |
32. Number of dialysis patients using a long-term central venous catheter on the last day of dialysis of the month |
1.00 |
33. Number of dialysis patients using AVF duration on the last dialysis day of the month |
1.00 |
34. Number of dialysis patients using PTFE prosthesis duration on the last day of dialysis of the month |
1.00 |
35. Hospitalization of dialysis patients due to clinical complications |
0.89 |
36. Death of patients under dialysis |
0.89 |
37. Seroconversion for positive Hepatitis C in patients undergoing Dialysis |
0.89 |
38. Seroconversion for positive Hepatitis B in patients undergoing Dialysis |
0.89 |
39. Hemoglobin value of dialysis patients |
1.00 |
40.Albumin value in dialysis patients |
1.00 |
41. Phosphorus value of dialysis patients |
1.00 |
42. PTH value of dialysis patients |
1.00 |
43. Ktv value of dialysis patients |
1.00 |
44. Patients eligible for transplant and older than 6 months on dialysis, enrolled in the CNPDO |
0.89 |
45. Matured AVF |
0.78 |
46. Adverse events (infection and signs of infection (shaking/fever/chills) |
0.78 |
|
46.1. Adverse events (rupture of dialyzer fibers) |
0.89 |
|
46.2. Adverse events (coagulation of the extracorporeal system) |
0.89 |
|
46.3. Adverse events (breakdown of the extracorporeal system) |
0.78 |
|
46.4. Adverse events (material defect) |
0.89 |
|
46.5. Adverse events (use of inappropriate material) |
0.89 |
|
46.6. Adverse events (capillary exchange between patients) |
0.89 |
|
46.7. Adverse events (AVF puncture error) |
0.78 |
|
46.8. Adverse events (hematoma) |
0.89 |
|
46.9. Adverse events (AVF rupture) |
0.89 |
|
46.10. Adverse events (accidental disconnection of the central venous catheter with the blood line) |
0.89 |
|
46.11. Adverse events (accidental disconnection of the fistula needle) |
0.89 |
|
46.12. Adverse events (reaction to sterilizer) |
0.89 |
|
46.13. Adverse events (reaction to transfusion of blood products) |
0.89 |
|
46.14. Adverse events (reaction to medication) |
0.89 |
|
46.15. Adverse events (reaction to dressings) |
0.89 |
|
46.16. Adverse events (skin injury) |
0.78 |
|
46.17. Adverse events (related to water treatment/distribution failure) |
0.89 |
|
46.18. Adverse events (related to the dialysis machine) |
0.89 |
|
46.19. Adverse events (patient fall) |
0.89 |
|
46.20. Adverse events (loss of access during dialysis) |
0.78 |
|
46.21. Adverse events (non-functioning central venous catheter) |
0.89 |
|
46.22. Adverse events (inadequate access blood flow) |
1.00 |
|
46.23. Adverse events (inadequate central venous catheter implantation) |
0.78 |
|
46.24. Adverse events (bleeding from venous access) |
0.78 |
|
46.25. Adverse events (dialysis prescription error) |
0.89 |
|
46.26. Adverse events (omission of care) |
0.78 |
47. Reason for entry (hypertensive nephrosclerosis; diabetic nephropathy; glomerulopathies; urological disease; chronic graft disease; cardiorenal; hepatorenal; patient in transit for parathyroidectomy surgery or for hospitalization for other reasons; systemic lupus erythema; other causes; exchange of therapy nephrotic syndrome; sepsis; polycystic disease or obstructive causes (myeloma). |
1.00 |
48. Patient withdrawal (change of therapy) |
0.89 |
|
48.1 Patient withdrawal (renal function recovery) |
0.89 |
|
48.2 Patient withdrawal (clinic transfer) |
0.89 |
|
48.3 Patient withdrawal (return to the clinic of origin), |
0,89 |
|
48.4 Patient withdrawal (patient in transit) |
078 |
|
48.5 Patient withdrawal (kidney transplant) |
0.89 |
|
48.6 Patient withdrawal (abandonment of treatment) |
0.89 |
49. Blood transfusion (red blood cells, platelets, plasma) |
1.00 |
50. Use of ferric hydroxide sucrate |
0.89 |
51. Use of EPO |
0.89 |
52. Clinical complications (hypotension, hypertension, nausea/vomiting, cramps, hypoglycaemia/hyperglycaemia) |
1.00 |
53. Monthly, semi-annual and annual blood collection |
0.78 |